Bora Pharmaceuticals Co (保瑞藥業) is still looking at contract development and manufacturing organizations (CDMOs) as potential merger and acquisition (M&A) targets, as the company continues to expand its business scale, the medicine and healthcare product maker said yesterday.
The company has seen its market value surge by more than 50-fold in seven years through a series of strategic M&As, including acquiring Japan-based Eisai Co’s subsidiary and plant in Tainan’s Guantian District (官田) in 2013 and US-based Impax Laboratories Inc’s subsidiary and plant in Miaoli County’s Jhunan Township (竹南) in 2018.
“We expect to see new M&A opportunities emerge next year,” Chinese-language online news outlet Cnyes.com quoted Bora Pharmaceuticals chairman Bobby Sheng (盛保熙) as saying. “There are not many buyers in the US M&A market and the valuations of many CDMOs are much cheaper than before, which is relatively beneficial to us.”
Photo: CNA
Sheng made the remarks at a ceremony at the Taiwan Stock Exchange (TWSE), where the company made its share debut on the main board after transferring its listing from the Taipei Exchange.
Bora Pharmaceuticals shares fell 3.1 percent to close at NT$657, in line with losses across the main exchange. Prior to yesterday, the stock had surged more than 60 percent since the beginning of this year.
Due to the growing market demand for drugs, several major clients have already discussed placing more orders, Bora Pharmaceuticals said.
As a result, the company has furthered its acquisition efforts, including factories, companies and product portfolios, it said.
It would also continue to adjust product strategy at its subsidiary TWi Pharmaceuticals Inc (安成藥) in a bid to diversify away from generic drugs, after the unit in August acquired six brand product licenses and technologies from Morristown, New Jersey-based Almatica Pharma Inc, it said.
The new strategy would enable Bora to leverage its sales platforms to enter the brand product market, create a new revenue driver and improve its profit margin, as well as allow the company to have more resources for future investment, it said.
Bora Pharmaceuticals’ consolidated revenue grew 50.25 percent year-on-year to NT$13.25 billion (US$422.5 million) in the first 11 months of this year, ranking second among Taiwanese pharmaceutical companies, TWSE data showed.
Net profit in the first three quarters totaled NT$2.47 billion, up 149.43 percent from the same period last year, with earnings per share rising from NT$10.12 to NT$24.63 and gross margin improving from 35.02 percent to 48.16 percent, the data showed.
RECYCLE: Taiwan would aid manufacturers in refining rare earths from discarded appliances, which would fit the nation’s circular economy goals, minister Kung said Taiwan would work with the US and Japan on a proposed cooperation initiative in response to Beijing’s newly announced rare earth export curbs, Minister of Economic Affairs Kung Ming-hsin (龔明鑫) said yesterday. China last week announced new restrictions requiring companies to obtain export licenses if their products contain more than 0.1 percent of Chinese-origin rare earths by value. US Secretary of the Treasury Scott Bessent on Wednesday responded by saying that Beijing was “unreliable” in its rare earths exports, adding that the US would “neither be commanded, nor controlled” by China, several media outlets reported. Japanese Minister of Finance Katsunobu Kato yesterday also
Taiwan’s rapidly aging population is fueling a sharp increase in homes occupied solely by elderly people, a trend that is reshaping the nation’s housing market and social fabric, real-estate brokers said yesterday. About 850,000 residences were occupied by elderly people in the first quarter, including 655,000 that housed only one resident, the Ministry of the Interior said. The figures have nearly doubled from a decade earlier, Great Home Realty Co (大家房屋) said, as people aged 65 and older now make up 20.8 percent of the population. “The so-called silver tsunami represents more than just a demographic shift — it could fundamentally redefine the
China Airlines Ltd (CAL, 中華航空) said it expects peak season effects in the fourth quarter to continue to boost demand for passenger flights and cargo services, after reporting its second-highest-ever September sales on Monday. The carrier said it posted NT$15.88 billion (US$517 million) in consolidated sales last month, trailing only September last year’s NT$16.01 billion. Last month, CAL generated NT$8.77 billion from its passenger flights and NT$5.37 billion from cargo services, it said. In the first nine months of this year, the carrier posted NT$154.93 billion in cumulative sales, up 2.62 percent from a year earlier, marking the second-highest level for the January-September
‘DRAMATIC AND POSITIVE’: AI growth would be better than it previously forecast and would stay robust even if the Chinese market became inaccessible for customers, it said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its full-year revenue growth outlook after posting record profit for last quarter, despite growing market concern about an artificial intelligence (AI) bubble. The company said it expects revenue to expand about 35 percent year-on-year, driven mainly by faster-than-expected demand for leading-edge chips for AI applications. The world’s biggest contract chipmaker in July projected that revenue this year would expand about 30 percent in US dollar terms. The company also slightly hiked its capital expenditure for this year to US$40 billion to US$42 billion, compared with US$38 billion to US$42 billion it set previously. “AI demand actually
RSS